Compositions and methods for treatment during non-acute periods following CNS neurological injury
This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.
1. A method for treating a neuroinjury resulting from a stroke in a mammal comprising administering a polypeptide comprising an epidermal growth factor like (EGF-like) domain of Glial Growth Factor 2 (GGF2), wherein the EGF-like domain comprises the amino acid sequence of SEQ ID NO: 18, to the mammal following said neuroinjury in said mammal, wherein the administering step is initiated at least one day after said neuroinjury.
2. The method of claim 1 , wherein said administering step begins at least three days after the neuroinjury.
3. The method of claim 1 , wherein said administering step begins at least seven days after the neuroinjury.
4. The method of claim 1 , wherein said mammal is a human.
5. The method of claim 1 , wherein the stroke is an ischemic stroke or a hemorrhagic stroke.
6. The method of claim 1 , wherein the GGF2 polypeptide is administered at a dose of 0.01-1 mg/kg bodyweight.
7. The method of claim 1 , wherein said administering step begins at least two days after the neuroinjury.
8. A method for treating a neuroinjury resulting from a stroke in a mammal comprising administering a polypeptide comprising an epidermal growth factor like (EGF-like) domain of Glial Growth Factor 2 (GGF2), wherein the EGF-like domain comprises the amino acid sequence of SEQ ID NO: 18, to the mammal following said neuroinjury in said mammal, wherein the administering step is initiated within six hours after said neuroinjury and wherein the administering step is continued into a time period more than six hours post injury.
9. The method of claim 8 , wherein the administering step is continued into a time period more than 48 hours post injury.
10. The method of claim 8 , wherein the administering step is continued into a time period more than 72 hours post injury.
11. The method of claim 8 , wherein said mammal is a human.
12. The method of claim 8 , wherein the stroke is an ischemic stroke or a hemorrhagic stroke.
13. The method of claim 8 , wherein the polypeptide is administered at a dose of 0.01-1 mg/kg bodyweight.
14. A method for treating an ischemic central nervous system neuroinjury in a mammal comprising administering a polypeptide comprising an epidermal growth factor like (EGF-like) domain of Glial Growth Factor 2 (GGF2), wherein the EGF-like domain comprises the amino acid sequence of SEQ ID NO: 18, to the mammal following neuroinjury in said mammal, wherein the administering step is initiated after the mammal has achieved a complete post-injury ischemic lesion cell death volume.
15. The method of claim 14 , wherein the neuroinjury results from a stroke.
16. The method of claim 14 , wherein the polypeptide is administered at a dose of 0.01-1 mg/kg bodyweight.